Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer Invests In Eye Firm EyeCyte
June 30, 2008
| A version of this story appeared in
Volume 86, Issue 26
Continuing its push for biotech partnerships and acquisitions, Pfizer has invested $3 million in EyeCyte, an early-stage stem- and progenitor-cell-based ophthalmology company in La Jolla, Calif. Pfizer, through its Biotherapeutics & Bioinnovation Center, will be the sole pharmaceutical partner of EyeCyte, which is based on the work of Scripps Research Institute scientist Martin Friedlander. Pfizer will also gain right of first refusal for a buyout of EyeCyte or its technologies. Pfizer recently formed a $9.5 million research collaboration with the California Institute for Quantitative Biosciences at the University of California, San Francisco (C&EN, June 16, page 34).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X